Targeting RAS Mutant Colorectal Cancer with Dual Inhibition of MEK and CDK4/6
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Research"
DOI: 10.1158/0008-5472.can-22-0198
Abstract: This co-clinical trial of combined MEK-CDK4/6 inhibition in RAS mutant colorectal cancer demonstrates therapeutic efficacy in patient-derived xenografts and safety in patients, identifies biomarkers of response, and uncovers targetable mechanisms of resistance. read more here.
Keywords: ras mutant; mek cdk4; mutant colorectal; colorectal cancer ... See more keywords